Pathogenetic Correction with Fingolimod of Disorders of Neurological and Neuropsychological Functions in Patients with Multiple Sclerosis


  • T.I. Negrych Lviv National Medical University named after Danylo Galytsky
  • S.Ya. Kyryliuk Lviv Regional Clinical Hospital, Lviv, Ukraine



multiple sclerosis, treatment, fingolimod


The results of clinical and neuropsychological examination of 7 patients with multiple sclerosis and their dynamics during treatment with fingolimod are presented in the article. The impact of fingolimod on neurological deficit, cognitive disorders, fatigue syndrome severity and quality of life of patients with multiple sclerosis are discussed. We have made the conclusion about the expediency of using pathogenetic preparation fingolimod in the treatment of patients with multiple sclerosis.


Лященко Е.А. Препарат финголимод в рамках современного подхода к лечению больных рассеянным склерозом // Русский медицинский журнал. — 2011. — № 31. —

Негрич Т.І., Євтушенко С.К., Сорокін Б.В., Москаленко М.А. Доказова база методів діагностики та лікування розсіяного склерозу // Міжнародний неврологічний журнал. — 2012. — № 5. — С. 215-222.

Столяров И.Д., Петров А.М., Ивашкова Е.В., Вотинцева М.В., Никифорова И.Г. Инновационный механизм действия препарата финголимод при рассеянном склерозе // Русский медицинский журнал. — 2011. — № 29. —

Шмидт Т.Е. Финголимод (Гилениа) — новый пероральный препарат для лечения ремиттирующего рассеянного склероза // Русский медицинский журнал. — 2012. — № 8.

Brinkmann V. Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology // Pharmacol. Ther. — 2007. — Vol. 115. — Р. 84-105.

Brinkmann V. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system // Br. J. Pharmacol. — 2009. — Vol. 158 (5). — Р. 1173-1182.

Brinkmann V., Davis M., Heise C. et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors // J. Biol. Chem. — 2002. — Vol. 277. — Р. 21453-21457.

Cohen J.A., Barkhof F., Comi G., Hartung H.P. et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis // N. Engl. J. Med. — 2010. — Vol. 362 (5). — Р. 402-415.

Dominguez M., Casals D., Sabate M. еt al. Prediction of pharmacokinetic/pharmacodynamic behaviour in humans of LAS189913, a S1P1 receptors agonist, based on preclinical studies in three animal species // Mult.Scl. — 2010 — V. 16, suppl. 10, S 150. — P. 453.

Foster C.A., Mechtcheriakova D., Storch M.K., Balatoni B., Howard L.M., Bornancin F., Wlachos A., Sobanov J., Kinnunen A., Baumruker T. FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage // Brain Pathol. — 2009. — Vol.19 (2). — Р.254-266.

Hla T. Signaling and biological actions of sphingosine 1-phosphate // Pharmacol. Res. — 2003. — Vol. 47 (5). — Р. 401-407.

Hohlfeld R., Calabresi P., O’Connor P. et al. Оral fingolimod (FTY720) reduces relapse rate in patients previously treated with disease-modifying therapies for multiple sclerosis and in patients who are treatment naiv: subgroup analysis of data from a 24-month phase III study (FREEDOM) // J. Neurol. — 2010. — v.257, suppl.1, S21.- Р.76.

Kappos L. et al. A Placebo-controlled study of oral Fingolimod in relapsing MS // N. Engl. J. Med. — 2010. — Vol. 362. — Р. 387-401.

Kappos L., Calabresi P., O Connor P. et al. Oral fingalimod (FTY720) has consistent, beneficial effects on disability progression outcomes in relapsing multiple sclerosis: 24-month, placebo-controlled results from phase III FREEDOMS study // J.Neurol. — 2010. — v. 257, suppl. 1, S144. — P. 445.

Kim S., Steelman A.J., Zhang Y., Kinney H.C.,

Li J. Aberrant upregulation of astroglial ceramide potentiates oligodendrocyte injury // Brain Pathol, epub ahead of print. — 2011,

May 25.

Meno-Tetang G.M., Li H., Mis S. et al. Physiologically based pharmacokinetic modeling of FTY720 in rats after oral and intravenous doses // Drug Metab Dispos. — 2006. — Vol. 34. —

Р. 1480-7.





To practicing Neurologist